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CytotoxicityProtein misfolding and aggregation are known to play a crucial role in a number of important
human diseases (Alzheimer’s, Parkinson’s, prion, diabetes, cataracts, etc.) as well as in a multitude
of physiological processes. Protein aggregation is a highly complex process resulting in a variety
of aggregates with different structures and morphologies. Oligomeric protein aggregates (amyloid
oligomers) are formed as both intermediates and ﬁnal products of the aggregation process. They
are believed to play an important role in many protein aggregation-related diseases, and many of
them are highly cytotoxic. Due to their instability and structural heterogeneity, information about
structure, mechanism of formation, and physiological effects of amyloid oligomers is sparse. This
review attempts to summarize the existing information on the major properties of amyloid
oligomers.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Misfolding and aggregation of polypeptides and proteins is a
central pathological and biochemical event shared by many neu-
rodegenerative maladies such as Alzheimer’s, Parkinson’s and
Huntington’s diseases and prion diseases, as well as other
human diseases, such as type II diabetes and systemic amyloi-
doses [1–3]. In addition, protein aggregates are believed to be
involved in several physiological processes such as hormone
storage [4] and memory formation [5–7]. Furthermore, many
biologically important proteins act in a form of speciﬁc
homo- or hetero-oligomers. Protein aggregates are usually either
classiﬁed as amyloid ﬁbrils (structures in which the polypeptides
are organized into cross-b sheets), amorphous aggregates, or sol-
uble aggregates often generically described as amyloid oligomers.
Amyloid oligomers are deﬁned as soluble non-monomeric
structures that appear as intermediates or ﬁnal products in the
process of protein aggregation lacking one or more of the
hallmarks of ﬁbrillar structure. Amyloid oligomers have been
reported for many disease-related proteins such as amyloid b,
huntingtin (Htt), a-synuclein, tau, and the prion protein [3,8–10].
They are highly heterogeneous in size, structure, stability andmorphology. Here we will describe amyloid oligomers based
on their major properties (Fig. 1) using a variety of aggregation-
prone proteins and peptides as examples.
2. Properties of amyloid oligomers
2.1. Secondary and tertiary structure
A number of complications are involved in preparation of even
reasonably homogeneous populations of amyloid oligomers. Many
amyloid oligomers are unstable and able to convert to more stable
oligomers or ﬁbrils over time. For example, Ab dimers previously
believed to be cytotoxic were shown to be inert but capable of con-
verting to larger cytotoxic oligomers [11]. In addition, existing
methods of oligomer characterization (e.g. SDS–PAGE, reactivity
of conformation-speciﬁc antibodies, DLS, various spectroscopic
methods) are not always able to distinguish different oligomer
populations and sometimes suffer from artefacts [12,13]. Despite
these complications, kinetically stable populations of amyloid oli-
gomers have been prepared from a variety of proteins, and the
peculiarities of their secondary and sometimes tertiary structures
have been analyzed. At the secondary structure level, these oligo-
mers have often been found to incorporate at least some
b-sheets, and in many (although not all) cases arrangement of
b-strands into b-sheets in oligomers was found to be antiparallel
[14–18]. This is distinct from amyloid ﬁbrils where, with a few
Fig. 1. Schematic representation of properties of amyloid oligomers.
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Examples of amyloid oligomer structures found in different
proteins are discussed below.
2.1.1. Amyloid b oligomers
Small Ab oligomers (dimers to tetramers) have been isolated
from in vivo sources and prepared in vitro. Their secondary struc-
ture was shown to be primarily disordered [22–25], and their
b-sheet content increased with increasing oligomer size [26].
Ab40 oligomers prepared in the physiologic-like conditions were
shown to have high b-sheet content, and molecular modeling pre-
dicted tertiary/quarternary structure of the oligomers to be similar
to that of ﬁbrils with some disruptions in the b-sheet stacking
[27,28]. Another population of Ab oligomers prepared under the
similar conditions had a more disordered secondary structure.
Crystallographic studies suggest that these oligomers may have
an antiparallel b-barrel like structure [15]. In the presence of lipid
bilayers, these oligomers could be converted to annular protoﬁbrils
also shown to be b-sheet rich [29,30].
Ab oligomers formed in the presence of EGCG appeared disor-
dered upon initial examination [31]. Subsequent NMR analysis
determined that in this oligomer population, C-terminal b-sheet
(residues 22–39) was included into the secondary structure forma-
tion, whereas the N-terminal half of the peptide was unstructured
due to the EGCG binding [32]. In Ab42 oligomers formed in the
presence of SDS, residues 25–40 were found to form b-strands that
were arranged in the antiparallel fashion, whereas the structure of
the N-terminal half of the peptide was unclear [14,18]. An EPR
investigation of oligomers prepared under the similar conditions
indicated gradual increase in the structural order towards the
C-terminus of the peptide and antiparallel arrangement of
b-strands [18]. NMR analysis of yet another population of Ab42 oli-
gomers (‘globulomers’) also formed in the presence of SDS sug-
gested the presence of a dimeric structural unit consisting of a
pair of in-register parallel b-strands formed by residues 34–40
extending from a b-hairpin formed by antiparallel arrangement
of two additional b-strand regions (18–23 and 28–33) [33](Fig. 2A). Overall, we can see that the Ab peptides form a wide vari-
ety of primarily b-sheet-rich oligomeric aggregates.
2.1.2. a-Synuclein oligomers
Oligomers of a-synuclein, similar to those of many other
amyloidogenic proteins, are highly structurally diverse. Three
broad classes of a-synuclein oligomers have been identiﬁed:
b-sheet-rich, primarily disordered and primarily a-helical.
Structural features of the b-sheet-rich oligomers (degree of dis-
order, surface exposure of hydrophobic residues, extent of the
b-structure, mechanical properties) were shown to be intermediate
between monomers and ﬁbrils [34–39]. Force spectroscopy [40]
and other methods [39] showed that a-synuclein oligomer stabil-
ity, b-sheet content, and size of the solvent-exposed hydrophobic
surfaces increased with the oligomer size. Analytical ultracentrifu-
gation (AUC) measurements combined with the H/D exchange
[41,42] and ﬂuorescence analyses [43] have shown that amyloid
core (residues 40–80) is consistently protected from the solvent
in oligomers, and in some oligomer preparations this protection
is extended on all N-terminal half of the protein (residues 1–90)
[41]. Oligomers with smaller solvent-protected core were shown
to be not on the pathway to ﬁbril formation, whereas the oligomers
with larger protected core were easily converted to ﬁbrils [41,44].
b-Sheet-rich a-synuclein oligomers were stable towards
thermal and urea denaturation and could be speciﬁcally detected
with the 9-(2,2-dicyanovinyl)julolidine ﬂuorescent dye [45].
Arrangement of b-strands in some of these oligomers was shown
to be antiparallel judging from FTIR spectra [17,38,43]. Another
population of oligomers was shown to possess a b-sheet rich hol-
low cylindrical architecture similar to that of ﬁbrils albeit with
higher degree of disorder [39]. Lorenzen and colleagues described
a globular ellipsoid oligomer containing 30 ± 6 a-synuclein mono-
mers with a compact interior of antiparallel b-strands and a sur-
rounding shell of disordered peptides [38].
Lipid-derived aldehydes such as HNE reacted with a-synuclein
to form lysine adducts and promoted formation of either
b-sheet-rich [46–48] or primarily disordered [49] oligomers,
Fig. 2. Structures of amyloid oligomers. A – globulomer, Ab42 [33]; B – hexamer, b2-microglobulin [85]; C – hexamer, PrP fragment [91]A; D – hexamer, aB-crystallin
fragment [15].
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formed after a-synuclein modiﬁcation with HNE were more stable
and less toxic than those formed in the presence of
4-oxo-2-nonenal [47]. A variety of aromatic molecules such as
EGCG [31,50,51], baicalein [52], dopamine [53–55], other polyphe-
nols [56], thioﬂavins [57], curcumin [58–60], an anti-PD drug
selengiline [61], b-hairpins [62] and many other compounds
[63,64] induced formation of mostly disordered a-synuclein oligo-
mers, although in some cases [52] the residual b-structure was
found. Many of these compounds were preferentially bound to
the C-terminus of a-synuclein [31,62,65]. Addition of EGCG to
the preformed b-sheet-rich oligomers did not lead to their disag-
gregation or loss of secondary structure but did inhibit their inter-
action with membranes [51]. Chemical modiﬁcations of
a-synuclein, such as methionine oxidation [66,67], intramolecular
crosslinking by transglutaminase [68,69], and formation of AGE
adducts [70,71], also promoted formation of the disordered oligo-
mers. However, other types of chemical modiﬁcation (e.g. tyrosine
nitration) stabilized b-sheet-rich oligomers and protoﬁbrils instead
[72–74].
Metastable a-helical oligomers of a-synuclein were observed
upon incubation of this protein with lipid membranes [75] and iso-
lated from in vivo sources although their prevalence in vivo is
unclear [76–79]. Under some conditions, the oligomers formed at
the early stages of a-synuclein aggregation were also found to be
primarily a-helical [80,81]. a-Helix rich oligomers and protoﬁbrils
were formed from the primarily disordered ones during incubation
at neutral pH (20 mM glycine, pH 7.5) and converted to ﬁbrils upon
further incubation [81]. These oligomers were intermediate instability between ﬁbrils and monomers, and had higher hydropho-
bic surface exposure than either ﬁbrils or monomers [81].
2.1.3. Other proteins
Structures of oligomers formed by other proteins and peptides
have been examined as well. For example, the aggregation of b-2
microglobulin (b-2m) at neutral pH was shown to be dependent
on the isomerization of His31-Pro32 bond from cis- to trans-con-
formation, leading to the partial unfolding of one of the b-strands
and to a consequent expose of a highly aggregation-prone region
of the protein [82]. Cu2+ ions were especially effective in catalyzing
this rearrangements, since they bind to His31 and can stabilize
partially unfolded conformations [83,84]. The role of these ions
has been conﬁrmed by the structural analysis of a Cu2+-bound
b-2m hexamer [85]. In these hexamers, His31-Pro32 bond was in
the trans-conformation, resulting in a partial rearrangement of
the protein structure and formation of the intermolecular interface
(Fig. 2B). Aggregation of b-2 microglobulin at acidic pH involved
more extensive unfolding of the protein. Various small oligomers,
up to hexamer, were observed, and, in fact, a hexamer has been
proposed to serve as a critical nucleus for ﬁbril formation under
these conditions [86]. Depolymerization of b-2 microglobulin ﬁb-
rils at pH 6.4 resulted in the formation of oligomers that appear
less structured than the ﬁbrils or monomers [87]. Association
interface in the oligomers was shown to be mediated by the inter-
actions between the D-strands of adjacent b-2m molecules based
on structural and kinetic studies [88,89].
Signiﬁcant amounts of b-structure have been detected in oligo-
mers of prion protein (PrP) [90,91]. PrP oligomers formed at low pH
Fig. 3. Morphology of amyloid oligomers. A – globular oligomers [28]; B – annular
protoﬁbrils [181].
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b-structure compared to ﬁbrils [90,92,93]. These oligomers were
not on the pathway for ﬁbril formation. Thermal unfolding of PrP
resulted in the formation of a different type of PrP oligomers,
where parts of C-terminal domain (residues 148–175) were
unfolded and then refolded to b-structure [94,95]. Crystal structure
of oligomers of a PrP-derived peptide [91] showed that this peptide
(residues 177–182 and 211–216 of PrP covalently linked via a
disulﬁde bond) was assembled into b-sheet-rich hexamers. The
overall structural organization of this hexamer was rather unique,
with three four-stranded, anti-parallel b-sheets being arranged like
the faces of a triangular prism (Fig. 2C). Assembly of subunits can
be described as a trimer of dimers, in which each four-stranded
b-sheet is formed by an association of two subunits along a twofold
axis, and the hexamer results from an association of dimeric
b-sheets along a threefold axis. Each hexamer has exposed
b-sheet strands that can be used for intermolecular contacts [91].
Crystallization of the oligomers formed by a fragment ofaB crys-
tallin allowed their structure to be determined at 1.4 Å resolution
[15]. The resulting hexamer was a six-stranded anti-parallel barrel
of cylindrical shape that resembled several previously proposed
b-barrel models (Fig. 2D). In this structure, each strand is bonded
to one neighboring strand by a strong interface and to a second by
a weak interface. Similar oligomers were formed by a b-2m derived
peptide [96]. Overall, the structure of this hexamer was similar to
that formed by the PrP-derived peptide (see above). Themain differ-
ence between these structures was the presence of exposed b-sheet
strands in the PrP peptide hexamer [91] and the absence of these
strands in the aB crystalline fragment hexamer [15].
2.1.4. Conclusions
Early stage oligomers formed from intrinsically disordered pro-
teins and peptides such as IAPP [97], PI3-SH3 domain [98], Ab [22–
25], and other peptides [99] were shown to be primarily unstruc-
tured. On the other hand, early stage oligomers derived from the
folded proteins such as insulin [100,101], SOD-1 [102], and
acylphosphatase [103,104] largely preserved the native fold of
these proteins. Formation of these early oligomers resembles the
process of the surfactant micelle formation, although due to the
required conformational changes in protein molecules, the oligo-
mer formation process is much slower [105]. As aggregation pro-
ceeds, oligomer size and b-sheet content increase [104,106]. In
some cases (e.g. a-synuclein), a-helical intermediates may also
be involved [80,81,107]. A number of stable, yet highly disordered
oligomers have been observed as well [32,67,108]. Gradual
increase in the oligomer size accompanied by conformational tran-
sition within the amyloid oligomers has been proposed to proceed
by monomer dissociation from the less stable oligomers followed
by association of this monomer with more stable aggregates
[109–111]. On the other hand, at least for some proteins and pep-
tides, the conversion of amyloid oligomers from native-like to
b-sheet rich forms has been shown to involve internal reorganiza-
tion rather than dissociation and reassembly [99,112,113]. Overall,
conformations of amyloid oligomers are highly diverse with a ten-
dency of increased b-sheet propensity with increasing oligomer
size.
2.2. Size, morphology, seeding ability and kinetic relationship to ﬁbrils
Amyloid oligomers vary in size from dimers to large multimers
consisting of 30–50 protein molecules. While oligomers usually
appear roughly globular in shape (Fig. 3A), in cases where detailed
structural information for oligomers is available, it is clear that
they often have complex structures. For example, Ab42 was shown
to form dodecamers that existed as dimers of ring-like hexamers
[114].In addition, Ab [29,30] and a-synuclein [115,116] oligomers can
assemble into annular protoﬁbrils, doughnut-shaped structures
with a centralized pore-like depression with an outer diameter of
8–12 nm, and an inner diameter of 2–2.5 nm (Fig. 3B). Oligomers
can also assemble into linear protoﬁbrils with beads-on-a-string
morphology [117,118].
Similar to ﬁbrils, a number of amyloid oligomers were shown to
self-propagate by seeding. In fact, there is some evidence that, in
addition to that of ﬁbrils, self-propagation of Ab [119,120] and
tau [120–122] amyloid oligomers plays an important role in neu-
rodegenerative diseases. Ab oligomers propagated faster than ﬁb-
rils [28], and oligomer seeding has been shown for tau [121,123],
a-synuclein [49,124], and ataxin [125]. Seeding was not com-
pletely sequence-speciﬁc, as cross-seeding was observed between
oligomers of Ab and tau [123], Ab40 and Ab42 [126], TDP-43 and
Ab [127], and human and rat IAPP [128]. Furthermore, hybrid oli-
gomers of a-synuclein and tau [129] as well as Ab and other
disease-related proteins [130] were detected in the brains of
patients with neurodegenerative diseases. Self-propagation of
amyloid oligomers by seeding refers to the process of
oligomer-catalyzed conversion of monomers to oligomers in a
manner similar to that of ﬁbrils. Similar to ﬁbrils, ‘daughter’ oligo-
mers preserve the conformation of the seeds. The difference
between ﬁbril and oligomer propagation is that oligomer propaga-
tion is accompanied by fragmentation of the resulting aggregates
that maintains their original size.
Kinetic relationship between amyloid oligomers and ﬁbrils has
long been a subject to intense debate. In terms of this relationship
oligomers are usually deﬁned as either ‘on-pathway’ or
‘off-pathway’ to ﬁbrils. The ‘on-pathway oligomers’ are deﬁned
as the ones capable of conversion or incorporation into the ﬁbrillar
structure without dissociating into monomers, while the
‘off-pathway oligomers’ are incapable of such conversion and must
transition to ﬁbrils via (partially unfolded) monomers (Fig. 4).
These types of oligomers can be distinguished by analyzing kinetic
data: addition of on-pathway oligomers to monomers should
accelerate ﬁbril formation while addition of off-pathway oligomers
should delay it. At this point no solid proof of existence of
on-pathway oligomers has been provided while a variety of
oligomers formed by different proteins and peptides have been
shown to be off-pathway [28,31,90,104,131,132]. That, of course,
does not preclude the possibility that the on-pathway oligomers
will be identiﬁed at the later date.
2.3. Relationship between oligomer structure and cytotoxicity
Progressive accumulation of structural information about amy-
loid oligomers allowed researchers to reveal some of the structural
features of these aggregates that account for their cytotoxicity:
small size and high surface hydrophobicity [133]. Multiple studies
Fig. 4. Potential energy proﬁles for the ‘on-pathway’ (A) and ‘off-pathway’ (B) amyloid oligomers.
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For example, for small Ab [26] and tau [134] oligomers, cytotoxic-
ity increased with oligomer size. However, for larger Ab oligomers
(12-mers or higher), cytotoxicity decreased with size [104],
suggesting that cytotoxicity may be maximal for the oligomers of
intermediate size.
In addition to size, structural features of oligomers have a sig-
niﬁcant effect on their toxicity. Toxic and non-toxic oligomers of
similar size and shape were compared for the bacterial protein
HypF-N, and one of the major differences between them was expo-
sure of hydrophobic surfaces [135]. Toxic oligomers had a less
well-packed hydrophobic core that resulted in solvent exposure
of the most hydrophobic regions of the protein sequence [135].
Partially disordered Ab oligomers formed in the presence of
polyphenols were non-toxic [31,136,137], whereas more struc-
tured Ab oligomers were toxic. Lysine-binding small molecules
(‘molecular tweezers’) were shown to promote formation of
non-toxic oligomers from a variety of amyloidogenic proteins
and peptides [138–142] by modulating the oligomer structure. In
case of Ab, they have been shown to compact the structures of
dimers and tetramers and prevented formation of more toxic
higher-order oligomers [143]. It has also been proposed that the
process of membrane-mediated aggregation of Ab is sufﬁcient to
cause cytotoxicity [144,145], possibly due to the formation of
transient, highly toxic oligomers.
3. Conformation-dependent antibodies as tools for
characterization of amyloid oligomers
Speciﬁc structural features of amyloid oligomers can be used as
antigens for conformation-speciﬁc antibodies. A wide variety of
such oligomer-speciﬁc antibodies is now available. For example,
NAB61 is a monoclonal antibody speciﬁc for Ab oligomers devel-
oped by synthesizing oligomeric aggregates from nitrated Ab and
using them as antigens [146]. Antibodies NU1, NU2 and NU4 used
small b-sheet rich Ab oligomers as antigens [147–149]. They are
speciﬁc for Ab oligomers although some of them (e.g. NU1 and
NU4) also recognize amyloid ﬁbrils [148]. An antibody (9D5) raisedagainst the pyroglutamate-modiﬁed Ab was shown to speciﬁcally
recognize only the oligomeric form of this peptide [150].
Anti-a-synuclein antibody 5G4 showed high speciﬁcity towards
b-sheet rich oligomers of this protein [74,151]. KW1 is a bivalent
antibody that speciﬁcally recognizes non-SDS stable Ab40 oligo-
mers with diameter of 17 nm [152], presumably by binding to
the motif formed by the residues 18–20 of the Ab peptide.
Antibodies speciﬁc for other Ab oligomers (amyloidosheproids,
globulomers) [153–155] and oligomers formed by other proteins
such as tau [156] and TDP-43 [157] have been described as well.
Some conformation-dependent antibodies recognize a speciﬁc
protein conformation in a sequence-independent manner, and this
recognition is presumably accomplished by binding to the protein
backbone. For example, polyclonal antibodies raised against pep-
tide oligomers have been shown to react with oligomers derived
from a wide variety of proteins and peptides [130,158–162]. It
has been proposed that these antibodies recognized the out of reg-
ister b sheets [15,163]. Several scFvs initially developed against
a-synuclein aggregates also recognized aggregates formed by
other proteins such as polyglutamines [164–168]. A variety of anti-
bodies raised against amyloid ﬁbrils can also recognize certain
b-sheet-rich oligomers formed by a variety of proteins and pep-
tides, presumably due to the similarities in the b-sheet packing
between these oligomers and ﬁbrils [169,159].
Conformation-speciﬁc antibodies can distinguish between
different conformations of amyloid oligomers
[158,159,166,170,171]. For example, two scFv fragments raised
against a-synuclein oligomers could distinguish between
oligomers of different size and morphology [166]. Reactivity with
polyclonal sequence-independent antibodies has been used to
propose separation of Ab oligomers into three distinct structural
classes [171]: ﬁbrillar, preﬁbrillar and annular. Oligomers
belonging to each class did not cross-react with antibodies speciﬁc
for another oligomer class. Fibrillar oligomers reacted with
ﬁbril-speciﬁc antibodies and were shown to have a cross-b struc-
ture similar to ﬁbrils [27,28]. Preﬁbrillar oligomers formed an
antiparallel b-barrel structure with the out of register b-sheets
[163,172]. Annular protoﬁbrils had a distinct ring-like morphology
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guish between different oligomer conformations within each of
the structural classes. Two distinct, self-propagating strains of pre-
ﬁbrillar Ab oligomers have been detected based on their antibody
reactivity and apparent size [173]. Structural differences between
ﬁbrillar Ab oligomers prepared under the different conditions
could be observed based on their reactivity with several
anti-ﬁbril antibodies [169].
4. Differences and similarities between amyloid oligomers and
functional protein complexes
What is the major difference between the amyloid oligomers
and functional homo- and hetero-oligomeric complexes formed
by the majority of cellular proteins [174]? While there is signiﬁ-
cant structural variability among both types of oligomers, func-
tional oligomers (especially homo-oligomers) tend to represent
deep minima on the potential energy surface while amyloid oligo-
mers usually correspond to a rugged potential energy surface with
several shallow minima. In structural terms, this means that func-
tional protein oligomers tend to have stable, compact, highly sym-
metrical structures with ﬁxed number of subunits and extensive
intersubunit contacts [174,175]. Amyloid oligomers, on the other
hand, tend to be less compact, have a higher degree of disorder
and variable stoichiometry.
However, there are several examples of functional protein oligo-
mers similar in structure to amyloid oligomers. They include milk
colloids [176] and oligomers of small heat shock proteins (sHsps)
[177–180]. sHsp monomers range in size from 10 to 40kDa and
are deﬁned by a conserved b-sandwich a-crystallin domain (about
90 residues), ﬂanked by variable and intrinsically disordered N- and
C-terminal domains. a-Crystallin domain plays an important role in
formation of stable sHsp dimers, which are the building blocks of
the large sHsp oligomers. Most sHsps form large oligomeric ensem-
bles with a broad distribution of different sphere- or barrel-like
morphologies, with the size and structure of the oligomers dictated
by the features of the N- and C-termini [177,178,180]. N-terminal
domains of sHsps interact with each other, with the core
a-crystallin domain of the same or neighboring dimers, and play
important role in formation of large sHsp oligomers. The
C-terminal extension interacts with target proteins and affects their
interaction with the a-crystallin domain. Such a variety of oligo-
meric complexes comes handy for interaction with a large range
of protein substrates. Hundreds of different stoichiometries of
chaperone–client interaction were observed, demonstrating that
an ensemble of structures underlies the protection chaperones con-
fer to unfolding clients. This is a clear indication that ﬂexible struc-
tures typical for amyloid oligomers can have a biological function.
5. Conclusions
Amyloid oligomers are formed as both intermediates and ﬁnal
products of aggregation process. They are believed to play an
important role in many protein aggregation-related diseases, and
many of them are highly cytotoxic. They tend to be highly struc-
turally variable. Early stage oligomers largely preserve the mono-
meric fold or lack thereof. Later stage oligomers tend to become
more structured as they increase in size. In a few cases where
three-dimensional structures of amyloid oligomers have been
determined, they were found to involve antiparallel b-strands or
b-barrels. Cytotoxicity of amyloid oligomers is usually correlated
with their size and hydrophobic surface exposure. There are sev-
eral examples of functional protein oligomers similar in structure
to amyloid oligomers including milk colloids and oligomers of
small heat shock proteins.References
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